Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.
DFR outlines Blue Cross losses and urges new oversight tools; board appointments debated
Loading...
Summary
The Department of Financial Regulation told the Senate Finance committee that Blue Cross experienced major underwriting and Medicare Advantage losses, prompting DFR actions to protect solvency. DFR recommended more regulatory tools; members debated whether appointing state members to the Blue Cross board or other governance changes would be effective.
The Department of Financial Regulation (DFR) provided a detailed account of recent financial strains at Blue Cross Blue Shield, telling the committee the insurer’s surplus fell dramatically over a multi‑year period due to underwriting losses, Medicare Advantage losses and pension impacts. "During a 3 year period, their surplus dropped over a 107,000,000," the Commissioner (S3) said, describing steps DFR has taken to restore solvency, including an order requiring Blue Cross to bring hospital contracts to DFR for review.
DFR described limits of its authority: unlike most other lines of insurance, DFR provides advisory input on rates for the state's domestic insurer and cannot directly set rates for some products. Committee members asked whether adding state appointees to Blue Cross’s board would have prevented the losses or would be effective going forward. DFR said board seats could have helped by providing an alternate perspective, but several senators warned that the company’s bylaws and the sole‑member governance structure (Michigan as sole member, per testimony) may blunt the influence of two state appointees.
Questions ranged from potential conflicts of interest to whether alternative regulatory tools (e.g., stronger reporting, bylaw changes, advisory duties or statutory powers) could better balance solvency and affordability. DFR officials emphasized that previous interventions — including hiring consultants, ordering contract reviews, and seeking reserve contributions — were instrumental in stabilizing the insurer. They also suggested applying principles of health‑care transformation more broadly and exploring structural changes such as a 1333 waiver or interstate collaboration for long‑term reform.
The Department of Vermont Health Access (DVHA) later requested two clarifying edits to H 5 85: exclude the large‑group market from DVHA’s reporting scope or shift that part of the analysis to DFR, and narrow a statutory cross‑reference to specific subsections of 8 V.S.A. § 4092 related to prescription drug out‑of‑pocket limits. Alex McCracken (S11) said DVHA can do the reporting it is asked to do but lacks large‑group market data and that the bill’s statutory citation should be tightened.
